Released April 5, 2019

Dechra Veterinary Products prides itself as a global leader in the ethical and responsible use of pharmaceuticals. The health of the horse is our first and foremost priority, and a driving force in our product development, commercialization and ongoing research efforts. We are passionate advocates of equine welfare and our people, science and products deliver on that passion every day.

When a part of our industry suffers, we all suffer, and the unfortunate circumstances at Santa Anita are no exception. The unscrupulous use of any health product is something we find not only morally reprehensible but also incredibly disheartening. Speculation around the potential causes of these incidents at Santa Anita is leading to confusion and creating uncertainty as to the use of bisphosphonates in horses. Dechra would like to offer clarification specific to its product, Osphos (clodronate injection).

“Dechra firmly believes Osphos is safe to use in horses when label directions are followed,” says Jill Stohs, DVM, director of pharmacovigilance and veterinary services for Dechra Veterinary Products. “Dechra does not market, promote, or condone the sale of Osphos for off-label use and has always advocated for the judicious use of our product. We have undertaken significant educational efforts since the product launched to inform the profession on the indicated safe use of the product and have a very high compliance rate with on-label use of the product, particularly in English sport and western performance horses